Laing R W, Warrington A P, Hines F, Graham J D, Brada M
Neuro-oncology Unit, Royal Marsden Hospital, Sutton, Surrey, U.K.
Eur J Cancer. 1993;29A(10):1387-91. doi: 10.1016/0959-8049(93)90007-3.
24 patients with 28 brain metastases were treated with fractionated stereotactic radiotherapy (SRT). Doses ranged from 10 Gy in two fractions to 20 Gy in two fractions. 13 patients received SRT boost after whole brain radiotherapy (WBRT), 5 were treated with SRT alone and 6 were treated at the time of recurrence following WBRT. The median progression-free survival at the treated site was 18 months and the median survival was 18 months. All patients were treated without admission to hospital. Toxicity of fractionated SRT was minimal and patients treated without WBRT did not suffer significant alopecia. Fractionated SRT offers a non-toxic non-invasive alternative to excision surgery in patients with solitary brain metastases. The optimum fractionation schedule and the role of whole brain irradiation remain to be determined.
24例患有28个脑转移瘤的患者接受了分次立体定向放射治疗（SRT）。剂量范围为分两次给予10 Gy至分两次给予20 Gy。13例患者在全脑放疗（WBRT）后接受了SRT强化治疗，5例仅接受SRT治疗，6例在WBRT复发时接受治疗。治疗部位的无进展生存期中位数为18个月，总生存期中位数为18个月。所有患者均无需住院治疗。分次SRT的毒性极小，未接受WBRT治疗的患者未出现明显脱发。分次SRT为孤立性脑转移瘤患者提供了一种无毒、非侵入性的手术切除替代方案。最佳分次方案和全脑照射的作用仍有待确定。
